In Silico Design of a Trans-Amplifying RNA-Based Vaccine against SARS-CoV-2 Structural Proteins

Area of Science:

• Vaccinology
• Immunology
• Computational Biology

Background:

• Nucleic acid vaccines offer rapid, scalable production for emerging infectious diseases like COVID-19.
• The SARS-CoV-2 pandemic highlighted the need for effective vaccine strategies against its structural proteins.

Purpose of the Study:

• To design a multiepitope messenger RNA (mRNA) vaccine targeting SARS-CoV-2 structural proteins (S, E, M, N).
• To computationally predict and select optimal epitopes for robust immune responses.
• To develop a trans-amplifying RNA (taRNA) vaccine system for enhanced immunogenicity.

Main Methods:

• Immunoinformatics approach to identify and select immunogenic epitopes.
• Molecular docking and dynamic simulations to assess vaccine construct stability and receptor interactions (TLR-2, TLR-3, TLR-4).
• Design of a split-vector taRNA vaccine system with a ribosomal adjuvant.

Main Results:

• Identified promising epitopes from SARS-CoV-2 structural proteins with high binding affinities to HLA class I and II.
• Construct 1 exhibited superior structural properties and favorable interactions with toll-like receptors.
• Immune response simulations predicted robust activation of B and T lymphocytes, memory cell formation, and high levels of IFN-γ and IL-2.

Conclusions:

• The designed multiepitope mRNA vaccine, incorporating a taRNA system and adjuvant, shows significant potential for eliciting a strong and durable immune response against SARS-CoV-2.
• Computational methods are effective for designing next-generation nucleic acid vaccines.